I still remember when immuno-oncology first started making waves. The buzz around checkpoint inhibitors was electric—PD-1, PD-L1, CTLA-4—suddenly, we were talking about cancer therapies that could unlock the immune system instead of just targeting the tumor. Fast forward a decade,…

As global trade dynamics shift yet again, the pharmaceutical industry is bracing for impact. Recent tariff developments—particularly the reintroduction of sweeping U.S. import duties—are prompting executives across healthcare and life sciences to revisit their sourcing strategies and cost structures. But…

When I first started working in the rare disease and gene therapy space, I thought the science would be the hardest part to wrap my head around. And don’t get me wrong—it’s complex. But what I didn’t fully appreciate at…

I’ll admit it—there was a time when neuroscience felt like a graveyard of pharma ambitions. I remember the wave of program terminations, the clinical failures, and the retreat from Alzheimer’s and Parkinson’s pipelines that felt almost industry wide. For a…

Picture this: You’re in a high-stakes chess match. The room is silent. The tension is thick. Every move counts. But instead of thinking ahead, you’re fixated on where your opponent used to be five turns ago. You can guess what…

A Preview of My Upcoming Talk: Presenting Pricing Insights That Resonate with Leaders Pricing strategies often rely on robust data—carefully researched, meticulously analyzed, and expertly compiled. Yet, even the most data-driven pricing recommendations can be met with hesitation, skepticism, or…

Introduction Background Drug pricing reform in the U.S., driven by legislative changes such as the Inflation Reduction Act (IRA) and ongoing policy initiatives, is set to significantly alter the pharmaceutical competitive landscape. These changes will influence market access, pricing strategies,…

Introduction Background CGMs have emerged as critical tools in diabetes management, enabling real-time tracking of glucose levels and improving patient outcomes. With the rise of digital health integration, AI- driven analytics, and expanding use cases beyond diabetes management, the CGM…

You can also read this article on LinkedIn. Competitive Intelligence (CI) professionals often find themselves in a paradox: the more seamlessly we integrate insights into decision-making, the less visible our value can seem. It’s the CI equivalent of being the…